Fernando Pontaza, Co-Founder of Invariantes sits down with David Weisburd to discuss setting up the first Guatemalan Venture Capital Fund and why he targets a 25% IRR. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction to Fernando Pontaza and venture capital in Guatemala (2:47) Development of the Guatemalan VC ecosystem and success stories (4:35) Hybrid investment models and convincing conservative investors (8:35) Sponsor: Bidav Insurance Group (9:28) Balancing IRR with consistent returns and emerging manager selection (14:34) Investing in emerging managers and anchor LP benefits (18:11) Diligence in co-investments and non-core competencies (21:36) Brand influence on investments and GP/LP relationship best practices (24:48) LPAC roles and best practices (25:28) Venture capital perspectives and strategies in Latin America (29:21) Diversification importance and LP success stories in venture capital (33:50) Closing remarks from Fernando Pontaza and outro

Winter Mead, Founder and CEO of Coolwater Capital sits down with David Weisburd to discuss the importance of emerging managers and how Coolwater Capital is building the YC for GPs. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction and common mistakes by managers (0:58) Creation and insights from CoolWater Capital and Hal Capital (4:21) Venture vs. other asset classes and its evolution (8:39) Scaling and positive selection of managers at CoolWater (14:37) Sponsor: Bidav Insurance Group (17:23) Traits of successful emerging managers and psychological predictors (20:37) Investment strategies during COVID and CoolWater cohort overview (22:31) CoolWater's Explore, Build, and Club programs (24:42) Feedback from emerging managers and high NPS score (25:46) Fundraising mistakes and data room requirements for emerging managers (33:35) The role of compliance in fundraising (35:29) Portfolio construction strategies and follow-on policies (39:44) The impact of not doing pro rata investments (42:29) CoolWater's mission and building a community for emerging managers (44:06) Identifying committed GPs and understanding LP value-add (45:28) Networking, governance, and changing GP/LP relationship expectations (49:02) Skills for maintaining active LP relationships and closing remarks

Jeff Galvin, CEO of Addimmune, sits down with David Weisburd to discuss cell and gene therapy, and how Addimmune is working on a functional solution for HIV. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Initial phase 1 results for HIV treatment and blood markers (2:09) Introduction to Jeff Galvin, CEO of Adimmune (2:21) Jeff Galvin's background and transition to gene therapy (8:06) Understanding gene therapy and its potential (11:53) Sponsor: Bidav Insurance Group (12:42) Discussing real successes in gene and cell therapy (16:11) The mechanism of HIV spread and immune system impact (20:13) AGT 103's development for curing AIDS (23:26) Safety and efficacy signals in gene therapy phase one (25:52) Comprehensive phase one study results and future plans (28:47) HIV treatment market from a financial perspective (30:20) The gene and cell therapy revolution (31:45) 10X Capital's public listing and recruitment strategies (34:04) Closing remarks and call to action

Joshua Berkowitz of Berkocorp, sits down with David Weisburd to discuss investing in venture capital as a family office and why all investors should care about IRR (and not TVPI). We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction to Joshua Berkowitz and fund return expectations (0:23) Underwriting to a 20% IRR and Joshua's background (2:09) Transitioning to venture capital and managing capital flows (4:14) Comparing IRR and MOIC in investment evaluation (5:31) Best practices for managing capital calls and time diversification (10:25) Strategies to stay in market and evaluate top emerging managers (15:52) Sponsor: Bidav Insurance Group (17:34) GP success stories and portfolio strategies (20:51) Consolidating return expectations for venture funds (23:00) Balancing portfolio concentration and diversification (24:50) Evaluating GP personalities and strategies for established funds (30:50) Differences between founder CEOs and operator CEOs (32:13) GP diligence and operational due diligence expectations (36:46) Fund documentation and portfolio construction for new managers (42:03) LP communication, strategy creep, and expectation management (47:12) Quarterly updates and LP versus VC value add (49:00) Follow on investment strategies and technical risks (55:20) Seed to series A graduation rates and LP lessons learned (59:03) Co-investment evaluation and LP portfolio management (1:01:31) Joshua's venture dexa.ai and data-driven decision making (1:10:45) Attracting talent and scaling strategies for tech startups (1:15:30) The significance of mentorship and early fundraising challenges (1:25:20) Learning from failed ventures and closing thoughts (1:38:00) Sponsor message: Wealthfront

Brian Abrahams, CEO of American Friends of Sheba Medical Center, sits down with David Weisburd to discuss its “Peace through Health Initiative” and how the hospital has been helping Israeli and Palestinian citizens during the current conflict. (0:00) Introduction by Brian Abrahams (0:22) Backgrounds of Brian Abrahams and Reese Powell (1:24) Sheba Hospital's response to October 7th incident (3:16) Sheba Medical Center's role and initiatives (6:56) Changing the narrative through healthcare (9:30) Innovations in remote pregnancy monitoring (10:50) Larry Klein's personal connection to Sheba Hospital (17:48) Sponsor: Friends of Sheba Hospital (18:29) National trauma and rehabilitation efforts (21:32) Medical challenges and success stories at Sheba Hospital (23:55) Sheba's impact on the Middle East and humanitarian work

Alex Edelson of Slipstream Investors, sits down with David Weisburd and Erik Torenberg to discuss the four sources of alpha for emerging managers (Sourcing, Picking, Winning, and Value-Add). We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction and characteristics of a good LP (0:50) Introduction of Alex Edelson (1:14) Overview of Slipstream's fund strategy and key factors in diligencing managers (6:03) Detailed diligence process and red flags for emerging managers (9:37) Challenges for emerging managers and institutionalizing courage (12:11) Sponsor: Bidav Insurance Group (13:07) Advising family offices and strategy behind Slipstream's concentrated portfolio (17:44) LP and GP relationship dynamics and special economics (21:38) Generalist versus specialist funds and the importance of sourcing (27:44) Building relationships for deal flow and winning deals in competitive rounds (33:03) The balance of fundraising and investing skills (35:00) Capital constraints, fund size, and alpha generation (38:21) Lessons from early stage fund successes and key learnings (43:16) Value addition by VCs, portfolio construction, and follow-on strategies (47:27) The difference between a good LP and a great LP (49:16) Strategic use of reserves and preserving ownership (56:40) Penalties for GPs and final thoughts on Slipstream's goals (58:07) Personal reflections and appreciation

Jake Paul and Joey Levy, co-founder of Betr, sit down with David Weisburd to discuss the sports betting industry and how to build a $100 billion company. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction of Jake Paul and his transition to boxing (2:32) Timing in boxing and venture capital (4:27) Jake Paul's career ambitions (6:16) Jake Paul's competitiveness and personal relationships (7:39) Role of psychedelics in Jake Paul's life (8:22) Jake Paul's marketing and "problem child" persona (10:28) Joey Levy on partnership dynamics with Jake Paul (13:50) Sponsor: Bidav Insurance Group (14:38) Better's culture and market position (18:01) Addressing the sports gaming market needs (21:23) David Weisburd on market and customer acquisition (23:27) Efficiency of Better's customer acquisition costs (25:53) Better's brand monetization and gaming focus (26:43) Better's performance and projections (29:32) Vision for Better's growth (31:24) Joey Levy's personal drive (32:06) Comparing motivations of different entrepreneurs (33:34) Closing remarks and outro

James Heath, Investment Principal at dara5, sits down with David Weisburd to discuss early stage venture. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction to James Heath and his background in smaller fund strategies (1:24) Early stage investment learnings from PwC experience (3:13) Evaluating founders and startup resilience (6:24) Darafive's investment approach and data utilization (12:12) Co-investment opportunities and check size strategy (15:53) Sponsor: Bidav Insurance Group (17:21) Building and maintaining GP relationships (22:46) Alignment and values in GP/LP dynamics (24:00) Venture capital power dynamics and current investment state (27:54) Venture capital advice for family offices (29:21) Role of fund managers in early-stage investments (31:57) The value and strategy of co-investments (36:46) Annual general meetings best practices (39:18) Cultivating LP relationships and venture capital dynamics (45:40) Future of venture capital and industry outlook (49:20) Recommendations for future podcast guests (50:00) European LP landscape and opportunities (51:12) Importance and performance of emerging managers (53:26) Closing remarks and special RFP to the community

Raja Doddala, Head of VC at Churchill Asset Management, sits down with David Weisburd to discuss how Churchill diligences managers, and the importance of integrity in a GP. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction and Raja Doddala's background (1:33) Overview of Churchill Asset Management and TIAA CREF (2:34) Decision-making and investment criteria at Churchill (4:05) Traits and integrity in GP relationships (7:00) Assessing integrity and judgment in venture capital (11:50) Venture capital networks and secondary market strategies (14:17) Sponsor: Bidav Insurance Group (15:07) Multi-vintage investment strategy and time diversification (17:57) Data's role and strategy discipline in investing (20:44) Insights from top VCs and investment approaches (23:08) VC specialization and entrepreneur-VC dynamics (25:12) David Clark's insights and opportunity funds (26:50) Co-investment strategies and diligence process (29:20) GP relationship building and role at TIAA CREF (32:08) Collaboration and influence in the LP community (35:48) David Swenson's principles in the current context (36:48) Closing remarks and outro

Avlok Kohli, CEO of AngelList sits down with David Weisburd and Erik Torenberg to discuss how he grew AngelList into a $4B dollar company. We’re proudly sponsored by Bidav Insurance Group, visit lux-str.com if you’re ready to level up your insurance plans. (0:00) Introduction of Avlok Kohli and discussion on entrepreneurial traits (1:39) Traits sought in founders and rationality of rejecting acquisition offers (4:08) Elon Musk's approach to maximizing impact and founder vs operator mentality (10:33) Balancing empathy and decisiveness in leadership (13:21) Sponsor: Badaav Insurance Group (14:11) Views on MBAs and the importance of emerging managers in the market (19:18) Adapting AngelList's GP product for larger funds and institutional LPs (21:22) The most popular AngelList products for GPs and optimal asset allocation (24:48) Balancing product philosophies and handling product failures at AngelList (31:07) Decision making in leadership, with examples from Square and Elon Musk (34:04) Building a business culture, managing turnover, and proprietary data insights (38:22) Learnings from AngelList's dataset for deal selection (41:37) Metrics for evaluating skill in generating alpha and AngelList's fund of funds strategy (43:38) Naval Ravikant's business strategy, superpower, and product-driven approach (46:41) Customer-driven product development vs. internal innovation at AngelList (48:39) Future vision, product roadmap, and upcoming initiatives for AngelList (50:47) Avlok Kohli on customer feedback and engagement (51:31) Closing remarks by David Weisburd and outro